Assetmark Inc. Has $2.21 Million Stock Holdings in STERIS plc (NYSE:STE)

Assetmark Inc. raised its holdings in shares of STERIS plc (NYSE:STE) by 3.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 10,034 shares of the medical equipment provider’s stock after acquiring an additional 354 shares during the period. Assetmark Inc.’s holdings in STERIS were worth $2,206,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Corient Private Wealth LLC increased its position in shares of STERIS by 1,473.6% in the 4th quarter. Corient Private Wealth LLC now owns 87,982 shares of the medical equipment provider’s stock valued at $19,343,000 after buying an additional 82,391 shares in the last quarter. D.A. Davidson & CO. increased its position in shares of STERIS by 9.9% in the 4th quarter. D.A. Davidson & CO. now owns 1,238 shares of the medical equipment provider’s stock valued at $272,000 after buying an additional 112 shares in the last quarter. Coldstream Capital Management Inc. increased its holdings in STERIS by 13.5% during the 4th quarter. Coldstream Capital Management Inc. now owns 11,224 shares of the medical equipment provider’s stock worth $2,467,000 after purchasing an additional 1,338 shares in the last quarter. UBS Group AG increased its holdings in STERIS by 13.2% during the 4th quarter. UBS Group AG now owns 162,769 shares of the medical equipment provider’s stock worth $35,785,000 after purchasing an additional 18,947 shares in the last quarter. Finally, Norges Bank bought a new position in STERIS during the 4th quarter worth about $220,954,000. Institutional investors own 94.69% of the company’s stock.

Insiders Place Their Bets

In other STERIS news, VP Renato Tamaro sold 1,154 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $231.64, for a total transaction of $267,312.56. Following the completion of the sale, the vice president now directly owns 6,677 shares in the company, valued at $1,546,660.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other STERIS news, SVP Cary L. Majors sold 2,024 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the sale, the senior vice president now directly owns 11,369 shares in the company, valued at $2,639,085.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Renato Tamaro sold 1,154 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $231.64, for a total transaction of $267,312.56. Following the sale, the vice president now owns 6,677 shares of the company’s stock, valued at $1,546,660.28. The disclosure for this sale can be found here. Insiders sold 7,762 shares of company stock worth $1,798,477 over the last three months. Insiders own 0.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, May 10th. Stephens restated an “overweight” rating and set a $250.00 price objective on shares of STERIS in a research note on Friday, February 9th. Piper Sandler restated a “neutral” rating and set a $225.00 price objective (up from $220.00) on shares of STERIS in a research note on Friday, May 10th. KeyCorp assumed coverage on shares of STERIS in a research note on Tuesday, February 6th. They set an “overweight” rating and a $253.00 price objective for the company. Finally, StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research note on Saturday, May 11th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.60.

STERIS Trading Up 1.0 %

Shares of NYSE:STE opened at $229.17 on Friday. STERIS plc has a 52-week low of $195.47 and a 52-week high of $254.00. The company has a market capitalization of $22.64 billion, a P/E ratio of 59.99 and a beta of 0.81. The company has a 50-day simple moving average of $216.92 and a 200 day simple moving average of $217.46. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.34 and a current ratio of 3.06.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.41 by $0.17. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The business had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.41 billion. During the same period last year, the business posted $2.30 EPS. STERIS’s revenue was up 10.8% on a year-over-year basis. Sell-side analysts forecast that STERIS plc will post 9.12 earnings per share for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 26th. Shareholders of record on Wednesday, June 12th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Wednesday, June 12th. This represents a $2.08 annualized dividend and a yield of 0.91%. STERIS’s dividend payout ratio (DPR) is presently 54.45%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.